Investor Presentaiton

Immunology LPA₁ Sotyktu ALOFT-IPF1 and ALOFT-PPF2: Two parallel Phase 3 registrational studies Key Inclusion: >40 yo (IPF); >21 yo (PPF) . FVC ≥40%, DLco >25% With or without concomitant background SoC Primary Endpoint: BMS-986278 (60 mg BID) Change in FVC (mL) at week 52 R 1:1:1 BMS-986278 (120 mg BID) Key Secondary Endpoint: Placebo Time to disease progression Patient-reported outcomes . Change in 6MWT 1. NCT06003426; 2. NCT06025578 Ill Bristol Myers Squibb™ Phase 3 studies initiating Data anticipated in 2026 (IPF) and 2028 (PPF) Primary Endpoint Week 52 CD19 NEX T Patients continue treatment and follow-up Not for Product Promotional Use 60

View entire presentation